Search Results
Your search for ,NOt matches 22378 pages
Showing 3651 - 3700Can Bariatric Surgery Decrease the Risk of Obesity-Related Cancers?
A new study presented at Digestive Disease Week 2023 has shown that just 4% of patients with obesity who underwent bariatric surgery developed obesity-associated cancer in a 10-year follow-up, compared with 8.9% among those who did not have a weight-loss procedure.1 These findings indicate that the ...
ASCO Member Testifies Before Congress to Urge Significant Increase in Federal Cancer Research Funding
The Association for Clinical Oncology (ASCO) continues to urge Congress to robustly fund the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Advanced Research Projects Agency for Health (ARPA-H) in Fiscal Year 2024. In testimony submitted to the Senate Committee on...
ASCO Updates Guideline for Management of Anxiety and Depression in Adult Cancer Survivors
Cancer takes a significant psychological toll on affected individuals. Cancer survivors have a significantly elevated risk of developing a mental health disorder compared with the general population, yet their psychological symptoms are often underrecognized and undertreated. To help equip...
Expert Point of View: Devraj Basu, MD, PhD, FACS
Devraj Basu, MD, PhD, FACS, of the Perelman School of Medicine, University of Pennsylvania, an expert in human papillomavirus (HPV)-related oropharyngeal cancer, commented on this study: “This abstract shows lack of awareness of multiple types of HPV-associated cancer and a reduced awareness of...
Better Awareness of HPV-Associated Cancers Is Still Needed in the United States, Study Finds
Awareness of the link between the human papillomavirus (HPV) and HPV-associated cervical cancers has declined over time, and awareness of other HPV-associated cancers, such as oral, penile, and anal, remains low, according to a cross-sectional study of the U.S. population presented at the 2023...
Expert Point of View: Matteo Lambertini, MD, PhD
Invited discussant of these two trials, Matteo Lambertini, MD, PhD, Associate Professor at the University of Genova–IRCCS Policlinico San Martino Hospital Genoa, Italy, emphasized the importance of longer follow-up periods for both these clinical trials and the need to wait for the additional...
Expert Point of View: Tina Cascone, MD, PhD
Discussant of the Neotorch study abstract, Tina Cascone, MD, PhD, of the Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, commended the authors for completing the initial analysis of the phase III randomized Neotorch trial, which...
Toripalimab Plus Chemotherapy Improves Event-Free Survival in Resectable Stage III NSCLC
Findings from a phase III, randomized trial highlight the benefit derived from perioperative immunotherapy in patients with early-stage resectable non–small cell lung cancer (NSCLC), according to data presented during the ASCO Plenary Series: April 2023 Session.1 Interim analysis of the Neotorch...
Pembrolizumab Added to Chemotherapy Improves Survival in Advanced Cervical Cancer Regardless of PD-L1 Expression
The addition of pembrolizumab to chemotherapy with or without bevacizumab led to improved overall survival and progression-free survival in women with persistent, recurrent, or metastatic cervical cancer in the final protocol-specified overall survival analysis of the KEYNOTE-826 trial presented at ...
Rethinking Prior Authorization
Prior authorization of medical procedures, services, and medications has been a standard requirement of health-care providers for decades. Rising health-care costs, specifically the escalating prices of cancer drug therapies, have led to a new focus by payers, providers, and policymakers on prior...
Reducing Air Pollution Globally May Contribute to Healthier Lifestyles and Lower Cancer Risks
The Union for International Cancer Control (UICC) has called for global action to improve public health and prevent millions of deaths from cancer and other noncommunicable diseases by drastically reducing air pollution in light of World Environment Day on June 5, 2023. "Creating cleaner and...
Cancer Survivors Who Quit Smoking May Have 36% Lower Cardiovascular Risk Than Those Who Continue Smoking
Patients who continue smoking after a cancer diagnosis may have almost a twofold risk of experiencing a heart attack, stroke, or death as a result of cardiovascular disease compared with nonsmokers, according to a new study published by Lee et al in the European Heart Journal. Background According...
NCCN Addresses Ongoing Chemotherapy Shortages as New Survey Suggests More than 90% of Cancer Centers May Be Impacted
Results of a new survey from the National Comprehensive Cancer Network (NCCN) have shed light on the widespread impact of the current carboplatin and cisplatin shortages. In a separate statement, the NCCN called on the whole oncology community to work together on solutions. Background Carboplatin...
Involving All of Society to End Cancer as We Know It
This has been a year of firsts and seconds for Monica M. Bertagnolli, MD, FACS, FASCO. This past October, Dr. Bertagnolli became the 16th Director of the National Cancer Institute (NCI), the first woman and the first clinical trials cooperative group chair to hold that position. Then, 2 months...
Second-Generation Antiandrogens and Cognitive and Functional Toxicity in Patients With Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Nowakowska et al found that use of second-generation antiandrogens for the treatment of prostate cancer was associated with increased risk of cognitive toxicity, fatigue, and falls in patients. Study Details The analysis included...
COMMANDS Trial: First-Line Luspatercept Boosts Chance of Transfusion Independence in Lower-Risk MDS
In the global phase III COMMANDS trial of patients with low-risk transfusion-dependent myelodysplastic syndrome (MDS), with or without ring sideroblasts, treatment with luspatercept essentially doubled the likelihood of achieving transfusion independence and an increase in hemoglobin level,...
Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with...
Cancer Survivors With Transportation Barriers to Care May Also Experience Financial Hardship, Food Insecurity, and Delays in Timely Care
Investigators have found that many U.S. cancer survivors with transportation barriers to care also reported struggling financially and experiencing additional barriers to timely care, according to new findings presented by Jiang et al at the 2023 ASCO Annual Meeting (Abstract 6534). Study Methods...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal cancer,...
Radiation Treatment May Not Be Necessary After Chemoimmunotherapy for Primary Mediastinal B-Cell Lymphoma
Results from the largest prospective study of patients with primary mediastinal B-cell lymphoma (PMBCL) showed that radiation therapy may be omitted in patients who have a complete metabolic response after chemoimmunotherapy. The IELSG37 international study found that these patients may be spared...
Stopping Immunotherapy After 2 Years vs Continuing Treatment May Yield Similar Survival Outcomes in Patients With Advanced NSCLC
Patients with advanced non–small cell lung cancer (NSCLC) may be able to stop receiving immunotherapy at 2 years as long as their cancer hasn’t progressed, according to new findings presented by Sun et al at the 2023 ASCO Annual Meeting (Abstract 9101) and simultaneously published in JAMA Oncology. ...
Exercise May Strengthen Immune System in Patients With Multiple Myeloma
Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....
Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel when compared to the current standard-of-care chemoimmunotherapy, according to results of the...
Cathy Eng, MD, and Lars Henrik Jensen, MD, PhD, on Locally Advanced Colon Cancer: Efficacy of Neoadjuvant Chemotherapy and Standard Treatment
Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Lars Henrik Jensen, MD, PhD, of the Danish Colorectal Cancer Center South and the University Hospital of Southern Denmark, discuss phase III results from the Scandinavian NeoCol trial, which showed that neoadjuvant chemotherapy is not superior...
Ciltacabtagene Autoleucel Reduces Risk of Disease Progression in Patients With Lenalidomide-Refractory Multiple Myeloma
Ciltacabtagene autoleucel, a B-cell maturation antigen–targeting chimeric antigen receptor (CAR) T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among patients with lenalidomide-refractory disease. Results from the...
Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib
Rana R. McKay, MD, of the University of California, San Diego, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discuss results from the phase III CONTACT-03 study, showing that, for patients with metastatic renal cell carcinoma (RCC), adding the PD-L1 inhibitor ...
Chemotherapy-Induced Peripheral Neuropathy May Be More Severe With Paclitaxel Than With Docetaxel
Researchers have found that patients who have breast cancer who undergo treatment with taxanes show a pattern of clinically meaningful, persistent sensory and motor symptoms associated with chemotherapy-induced peripheral neuropathy, according to new findings presented by Trivedi et al at the 2023...
Black Patients With Metastatic Prostate Cancer May Benefit From Apalutamide and Abiraterone Acetate Plus Prednisone
The combination of apalutamide and abiraterone acetate plus prednisone, which previously demonstrated little overall survival benefit in White patients with metastatic prostate cancer, may yield better survival outcomes in Black patients with the disease, according to new findings presented by...
Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico
Paula Aristizabal, MD, MAS, of the University of California, San Diego, and Rady Children’s Hospital, talks about using a health systems strengthening approach to improve leukemia care and survival in a public Mexican hospital in the region of the border between the United States and Mexico. The...
Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130
Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to induction therapy with atezolizumab plus platinum and gemcitabine did not seem to impact overall survival for patients with metastatic urothelial carcinoma....
Radiation May Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy may safely forgo radiation therapy before surgery, based on the findings of the PROSPECT trial. These data were presented by Deborah Schrag, MD, FASCO, MPH, at the 2023 ASCO Annual Meeting (Abstract LBA2) and...
Vorasidenib Delays Disease Progression or Death in Patients With Grade 2 IDH-Mutated Glioma
Vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with grade 2 gliomas. This treatment delayed disease progression and was well tolerated. These findings from the INDIGO trial represent a significant step forward in the...
Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment
Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes...
Mirvetuximab Soravtansine Improves Survival in Patients With Recurrent Ovarian Cancer
The international phase III MIRASOL randomized clinical trial found that mirvetuximab soravtansine-gynx, an antibody and microtubule inhibitor conjugate, significantly improved progression-free and overall survival for patients with platinum-resistant, advanced high-grade epithelial ovarian,...
Nivolumab May Reduce Risk of Disease Progression or Death in Previously Untreated Patients With Hodgkin Lymphoma Compared to Brentuximab Vedotin
The immune checkpoint inhibitor nivolumab plus chemotherapy significantly reduced the risk of disease progression and disease-related death compared with standard treatment with the CD30-targeted drug brentuximab vedotin plus chemotherapy in pediatric and adult patients with previously untreated...
Is Pembrolizumab Effective in Patients With Brain Metastases?
In a phase II clinical trial, investigators found that 42% of patients with brain metastases benefited from treatment with the immune checkpoint inhibitor pembrolizumab, with 7 of the 57 patients in the trial surviving for longer than 2 years. The study authors cautioned that these benefits must be ...
Veterans Exposed to Agent Orange May Be at Increased Risk of Developing Myeloproliferative Neoplasms
A population-based study using information from a database of veterans found that those who had been exposed to Agent Orange may be at an increased risk of developing myeloproliferative neoplasms (MPNs). Agent Orange is a herbicide that was used by the U.S. military in Korea and Vietnam to clear...
Early Cessation of Neoadjuvant Chemotherapy May Lead to Worse Outcomes in Patients With Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to cystectomy may have an increased risk of cancer recurrence and worse survival outcomes, according to the findings of a retrospective study presented by Chakraborty et al at the 2023 ASCO Annual ...
Adding Ribociclib to Endocrine Therapy May Reduce Recurrence Risk in Patients With Hormone Receptor–Positive, HER2-Negative Early-Stage Breast Cancer
Adding the CDK4/6 inhibitor ribociclib to endocrine therapy resulted in a significant improvement in invasive disease–free survival for patients with hormone receptor–positive, HER2-negative early-stage breast cancer. Findings from the phase III NATALEE trial were presented by Dennis J. Slamon, MD, ...
Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer
Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from the large, international phase III SHAPE clinical trial. The research was presented by Plante...
Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection
Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The...
Extended Lymphadenectomy May Not Benefit Patients With Clinically Localized Muscle-Invasive Bladder Cancer
Extended lymphadenectomy in patients undergoing radical cystectomy for clinically localized muscle-invasive bladder cancer was not associated with improved disease-free survival or overall survival and may increase the risk of adverse events and postsurgical mortality, according to new findings...
Study Finds Wide Variations in Intratumoral Microbiome of Patients With Early- vs Late-Onset Colorectal Cancer
Researchers have found that the bacteria, fungi, and viruses within the tumors of patients with colorectal cancer varied significantly depending on whether they were diagnosed with early-onset or late-onset disease, according to new findings presented by Weinberg et al at the 2023 ASCO Annual...
ATOM Coalition Seeks to Ensure Equitable Cancer Care in Low- and Middle-Income Countries
A new global health initiative, the Access to Oncology Medicines (ATOM) Coalition, may be capable of reducing the burden of suffering and death from cancer in low- and middle-income countries by improving patient access to essential cancer medicine. Gilberto Lopes, MD, FASCO, MBA, will highlight...
FDA Approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 31, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
Daughter of Immigrants Who Fled the Pogroms, She Followed a Love of Science Into a Noted Career in Cancer Pathology
In the era of genomics and precision medicine, the role of pathology in diagnosis and cancer management is rapidly evolving. For the past 50 years, from her office at the Center for Cancer Research, National Cancer Institute (NCI), pathologist Elaine S. Jaffe, MD, has been at the forefront of that...
SGLT2 Inhibitors and Cardiovascular Outcomes in Older, Anthracycline-Treated Patients With Cancer
In a population-based cohort study reported in JACC: CardioOncology, Abdel-Qadir et al found that receipt of sodium glucose cotransporter-2 (SGLT2) inhibitors was associated with a reduced risk of hospitalization for heart failure—but not risk for heart failure—among patients aged ≥ 65 years with...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
An Oncology Leader Whose Immigrant Parents Taught Him by Example About Life and Service to Humanity
According to Sunil R. Hingorani, MD, PhD, his parents figured heavily on who he became as a person and on his career choices, which ultimately led to his current position as Director of the Pancreatic Cancer Center of Excellence at the University of Nebraska College of Medicine, Omaha. “My father...
